NAC Attack

NAC Attack—A Multicenter Placebo-Controlled Clinical Trial to Test Oral N-Acetylcysteine in Patient

NAC is a strong antioxidant that reduces oxidative damage. NAC Attack is a randomized, placebo controlled multicenter trial that will test whether NAC can slow progression of RP. The results are critical to the RP community because if NAC proves beneficial it will mean life-long treatment with NAC for patients with RP. We understand the anxiety and concerns that RP causes, but it is best to avoid self-medication with supplements.

Frequently Asked Questions


Clinical Sites


NAC Attack clinical sites have been chosen and screening will begin in early 2023. If you are interested in participating in this study, contact the site location that is convenient for you now to assess potential eligibility.

NAC Attack Clinical Site Locations (Excel file) 

Supporting Organizations

  • Zambon SpA, Milan, Italy
  • Usher 2020
  • Fighting Blindness Canada

NAC Attack Leadership

Study Chairman's Office

Coordinating Center

NAC Attack Data Safety Monitoring Committee (DSMC)

Chair: Steven Piantadosi, M.D., Ph.D.
Biostatistics and Oncology, Brigham and Women's Hospital, Harvard University

Elise Heon, M.D.
Ophthalmology and Vision Sciences, University of Toronto

Judith Hochman, M.D.
Cardiology and Clinical Trials, New York University

David C. Musch Ph.D., M.P.H.,
Epidemiology and Ophthalmology, University of Michigan

Stephen H. Tsang, M.D., Ph.D.
Ophthalmology, and Pathology and Cell Biology, Columbia University

David N. Zacks, M.D., Ph.D.
Ophthalmology and Visual Sciences, University of Michigan

Alison Bateman-House, Ph.D.
Population Health, New York University


Contact the NAC Attack team to learn more.